Pharmacologic management of non-neurogenic functional obstruction in women

被引:8
|
作者
Cohn, Joshua A. [1 ]
Brown, Elizabeth T. [1 ]
Reynolds, W. Stuart [1 ]
Kaufman, Melissa R. [1 ]
Dmochowski, Roger R. [1 ]
机构
[1] Univ Med Ctr, Dept Urol Surg, 1302A Med Ctr North, Nashville, TN 37203 USA
关键词
Women; urinary retention; functional obstruction; voiding dysfunction; primary bladder neck obstruction; pharmacology; BLADDER NECK OBSTRUCTION; URINARY-TRACT SYMPTOMS; BOTULINUM-A TOXIN; BENIGN PROSTATIC HYPERPLASIA; PELVIC FLOOR DYSFUNCTION; PLACEBO-CONTROLLED TRIAL; VOIDING DYSFUNCTION; SACRAL NEUROMODULATION; URETHRAL SPHINCTER; OUTLET OBSTRUCTION;
D O I
10.1080/17425255.2016.1178239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Impaired bladder emptying in women without neurologic disease may be related to urethral obstruction and/or impaired bladder contractility. Mechanical obstruction generally requires surgical management and options are limited for impaired bladder contractility. However, functional obstruction from voiding dysfunction or primary bladder neck obstruction may present an opportunity for pharmacologic intervention. Areas covered: In this review, the authors extensively reviewed available literature regarding the use of off-label medications for functional bladder outlet obstruction in women. In addition, side effect profiles and pharmacology of these medications determined from on-label indications are reviewed. Specific medications reviewed include vaginal diazepam, baclofen, urethral botulinum toxin injection, and alpha-adrenergic blockers. Expert opinion: Alpha-blockers in particular have demonstrated promise in women with demonstrable or suspected bladder outlet obstruction with side effect profiles similar to those observed in men. However, lack of quality data hinders informed decision making with alpha-blockers or any of the other agents studied in women with non-neurogenic functional outlet obstruction. In the absence of well-designed, placebo-controlled multi-institutional trials, those prescribing these medications must be aware of special considerations and side effects associated with relatively unfamiliar treatments in the context of uncertain benefit.
引用
收藏
页码:657 / 667
页数:11
相关论文
共 50 条
  • [21] HoLEP for acute and non-neurogenic chronic urinary retention: how effective is it?
    Tevita Aho
    William Finch
    Philippa Jefferson
    Lokesh Suraparaju
    Fanourios Georgiades
    World Journal of Urology, 2021, 39 : 2355 - 2361
  • [22] Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome?
    Tellenbach, Marc
    Schneider, Marc
    Mordasini, Livio
    Thalmann, George N.
    Kessler, Thomas M.
    WORLD JOURNAL OF UROLOGY, 2013, 31 (05) : 1205 - 1210
  • [23] Non-neurogenic urinary retention (Fowler's syndrome) in two sisters
    Podnar, Simon
    Barbic, Matija
    NEUROUROLOGY AND URODYNAMICS, 2006, 25 (07) : 739 - 741
  • [24] HoLEP for acute and non-neurogenic chronic urinary retention: how effective is it?
    Aho, Tevita
    Finch, William
    Jefferson, Philippa
    Suraparaju, Lokesh
    Georgiades, Fanourios
    WORLD JOURNAL OF UROLOGY, 2021, 39 (07) : 2355 - 2361
  • [25] Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction
    Smith C.P.
    Somogyi G.T.
    Chancellor M.B.
    Current Urology Reports, 2002, 3 (5) : 382 - 387
  • [26] EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction
    Gratzke, Christian
    Bachmann, Alexander
    Descazeaud, Aurelien
    Drake, Marcus J.
    Madersbacher, Stephan
    Mamoulakis, Charalampos
    Oelke, Matthias
    Tikkinen, Kari A. O.
    Gravas, Stavros
    EUROPEAN UROLOGY, 2015, 67 (06) : 1099 - 1109
  • [27] Third-Line Therapeutic Interventions for Non-Neurogenic Bladder Dysfunction in Children
    Lombardo, Alyssa M.
    Alpert, Seth A.
    CURRENT UROLOGY REPORTS, 2024, 25 (12) : 331 - 338
  • [28] Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms
    Soler, Roberto
    Andersson, Karl-Erik
    Chancellor, Michael B.
    Chapple, Christopher R.
    de Groat, William C.
    Drake, Marcus J.
    Gratzke, Christian
    Lee, Richard
    Cruz, Francisco
    EUROPEAN UROLOGY, 2013, 64 (04) : 610 - 621
  • [29] Clinical characteristics and useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms
    Matsukawa, Yoshihisa
    Yoshida, Masaki
    Yamaguchi, Osamu
    Takai, Shun
    Majima, Tsuyoshi
    Funahashi, Yasuhito
    Yono, Makoto
    Sekido, Noritoshi
    Gotoh, Momokazu
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (01) : 47 - 52
  • [30] Functional changes during the voiding phase in men with non-neurogenic detrusor underactivity undergoing bladder catheterization
    Virseda-Chamorro, Miguel
    Salinas-Casado, Jesus
    Fuertes, Manuel Esteban
    Rubio, Santiago Mendez
    CONTINENCE, 2022, 2